FDA Approves Halaven for Advanced Liposarcoma

Share this content:
FDA Approves Halaven for Advanced Liposarcoma
FDA Approves Halaven for Advanced Liposarcoma

THURSDAY, Jan. 28, 2016 (HealthDay News) -- Halaven (eribulin mesylate) has been approved by the U.S. Food and Drug Administration as the first chemotherapy drug shown to improve survival in people with advanced liposarcoma.

The drug is sanctioned for patients who have received prior chemotherapy that contained an anthracycline drug, the agency said Thursday in a news release.

Halaven was evaluated in clinical studies involving 143 people with advanced liposarcoma that was unresectable or had spread to nearby lymph nodes or other parts of the body. Average survival among patients who took Halaven was 15.6 months, compared to 8.4 months among those who took dacarbazine.

The most common side effects of Halaven included fatigue, nausea, hair loss, constipation, peripheral neuropathy, abdominal pain, and fever. Other adverse reactions included neutropenia and decreased levels of potassium or calcium. More serious side effects included neuropathy, QTc prolongation, and harm to an unborn fetus, the FDA said.

Halaven is marketed by Woodcliff Lake, N.J.-based Eisai Inc.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Some California Mosquitoes Can Carry Zika Virus

Some California Mosquitoes Can Carry Zika Virus

Aedes aegypti mosquitoes found to transmit Zika virus

Periodontal Inflammation a Risk With Tongue Piercing

Periodontal Inflammation a Risk With Tongue Piercing

And, two young females with tongue piercings have deep lingual infrabony lesions, periodontitis

Risk of OD Highest for First Days of Opioid  Benzodiazepine Use

Risk of OD Highest for First Days of ...

Five-fold increased risk of opioid-related overdose during first 90 days of concurrent use

is free, fast, and customized just for you!




Already a member?

Sign In Now »